Safety and in vivo detection of GD2-specific 4SCAR-T cells
ADVERSE EVENT
To evaluate the safety of the delivery method of CAR-T cell infusion, either through the peripheral blood system or intracranial, the trial was designed with intravenous administration alone or intravenous combined with intracavitary administration. Eight patients received 11 infusions, with three patients receiving combined infusions (intravenous combined intracavitary administration; Table 
Adverse events within the first 4 weeks after GD2-specific 4SCAR-T cell infusion
Scores for Health-Related Quality of Life post GD2 specific 4SCAR-T cell infusion
In vivo persistence of GD2-specific 4SCAR-T cells in peripheral blood. The copy number of GD2-specific 4SCAR-T cells in peripheral blood of indicated patients was determined by RT-qPCR analysis